CytomX Therapeutics (NASDAQ: CTMX) saw its stock plummet 6.92% in pre-market trading on Friday, following the release of its disappointing third-quarter 2025 financial results. The cancer immunotherapy company's earnings and revenue figures fell significantly short of analyst expectations, triggering a sell-off among investors.

The company reported a quarterly loss of $0.09 per share, missing the analyst consensus estimate of $0.05 by a wide margin. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.96 million, falling well below the analyst estimate of $11.63 million and marking an 82.2% decrease compared to the $33.43 million reported in the previous year's quarter.

Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. CytomX attributed the revenue decline to the completion of Bristol Myers Squibb collaboration obligations and reduced Moderna activities. Looking ahead, the company continues to focus on its clinical programs, with ongoing progress in the CX-2051 Phase 1 trial and a data update expected in the first quarter of 2026.